Cited by 1,064Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune cells in cancer

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

Muller, Alexander J, DuHadaway, James B, Donover, P Scott, Sutanto-Ward, Erika, Prendergast, George C·2005·Nature Medicine

DOI 10.1038/nm1196

Open this paper in CoChat — free account

Abstract

Immune escape is a crucial feature of cancer progression about which little is known. Elevation of the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) in tumor cells can facilitate immune escape. Not known is how IDO becomes elevated or whether IDO inhibitors will be useful for cancer treatment. Here we show that IDO is under genetic control of Bin1, which is attenuated in many human malignancies. Mouse knockout studies indicate that Bin1 loss elevates the STAT1- and NF-kappaB-dependent expression of IDO, driving escape of oncogenically transformed cells from T cell-dependent antitumor immunity. In MMTV-Neu mice, an established breast cancer model, we show that small-molecule inhibitors of IDO cooperate with cytotoxic agents to elicit regression of established tumors refractory to single-agent therapy. Our findings suggest that Bin1 loss promotes immune escape in cancer by deregulating IDO and that IDO inhibitors may improve responses to cancer chemotherapy.

Integrity signals

Registry

Crossref · 10.1038/nm1196

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Current Protocols in Immunology
(2018) · Current Protocols in Immunology · doi:10.1002/(issn)1934-368x · Cited by 3,574
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1252 · Cited by 1,660
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I. E., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,640
BAR Domains as Sensors of Membrane Curvature: The Amphiphysin BAR Structure
Peter, B. J., Kent, H. M., Mills, I. G., Vallis, Y., Butler, P. J. G., Evans, P. R., & McMahon, H. T. (2004) · Science · doi:10.1126/science.1092586 · Cited by 1,636
Current protocols in immunology
Nezlin, R. S. (1992) · Molecular Immunology · doi:10.1016/0161-5890(92)90114-d · Cited by 1,413
Colorectal carcinoma antigens detected by hybridoma antibodies
Koprowski, H., Steplewski, Z., Mitchell, K. F., Herlyn, M., Herlyn, D., & Fuhrer, P. (1979) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01542654 · Cited by 1,360
Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,185

Flagged first, then by citations

Show all 54 references

Sorted by citations

Items 401–500 of 999

The Role of the Kynurenine/AhR Pathway in Diseases Related to Metabolism and Cancer
Shadboorestan, A., Koual, M., Dairou, J., & Coumoul, X. (2023) · International Journal of Tryptophan Research · doi:10.1177/11786469231185102 · Cited by 58
Diverse Physiological Roles of Kynurenine Pathway Metabolites: Updated Implications for Health and Disease
Wang, Y., Zhang, Y., Wang, W., Zhang, Y., Dong, X., & Liu, Y. (2025) · Metabolites · doi:10.3390/metabo15030210 · Cited by 59
Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas
Laimer, K., Troster, B., Kloss, F. R., Schäfer, G., Obrist, P., Perathoner, A., Laimer, J., Brandacher, G., Rasse, M., Margreiter, R., et al. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.03.007 · Cited by 54
Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen
Smith, J. R., Evans, K. J., Wright, A., Willows, R. D., Jamie, J. F., & Griffith, R. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.10.068 · Cited by 54
Overexpression of Indoleamine 2,3-Dioxygenase in Human Endometrial Carcinoma Cells Induces Rapid Tumor Growth in a Mouse Xenograft Model
Yoshida, N., Ino, K., Ishida, Y., Kajiyama, H., Yamamoto, E., Shibata, K., Terauchi, M., Nawa, A., Akimoto, H., Takikawa, O., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0991 · Cited by 54
Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors
Dolušić, E., Larrieu, P., Blanc, S., Sapunaric, F., Pouyez, J., Moineaux, L., Colette, D., Stroobant, V., Pilotte, L., Colau, D., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.02.049 · Cited by 54
Discovery and structure–activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors
Cheng, M.-F., Hung, M., Song, J., Lin, S., Liao, F.-Y., Wu, M.-H., Hsiao, W., Hsieh, C., Wu, J., Chao, Y., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.05.084 · Cited by 55
Tryptophan‐2,3‐dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor‐4
Ochs, K., Ott, M., Rauschenbach, K. J., Deumelandt, K., Sahm, F., Opitz, C. A., von Deimling, A., Wick, W., & Platten, M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13503 · Cited by 55
A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer
Soliman, H. H., Khambati, F. A., Han, H. S., Ismail-Khan, R. R., Bui, M. M., Sullivan, D. M., & Antonia, S. J. (2018) · Oncotarget · doi:10.18632/oncotarget.24118 · Cited by 54
Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development
Zhu, M. M. T., Dancsok, A. R., & Nielsen, T. O. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0750-1 · Cited by 55
Tumor resistance mechanisms and their consequences on γδ T cell activation
Wesch, D., Kabelitz, D., & Oberg, H. (2020) · Immunological Reviews · doi:10.1111/imr.12925 · Cited by 56
What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past
Yu, Y., Liang, H., Fang, X., Zhang, S., Xing, Z., Shi, L., Kuang, C., Seliger, B., & Yang, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01847-4 · Cited by 55
The role of RIPK1 mediated cell death in acute on chronic liver failure
Kondo, T., Macdonald, S., Engelmann, C., Habtesion, A., Macnaughtan, J., Mehta, G., Mookerjee, R. P., Davies, N. A., Pavesi, M., Moreau, R., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04442-9 · Cited by 52
AhR diminishes the efficacy of chemotherapy via suppressing STING dependent type-I interferon in bladder cancer
Ma, Z., Li, Z., Mao, Y., Ye, J., Liu, Z., Wang, Y., Wei, C., Cui, J., Liu, Z., & Liang, X. (2023) · Nature Communications · doi:10.1038/s41467-023-41218-5 · Cited by 57
Interferon-γ induces a tryptophan-selective amino acid transporter in human colonic epithelial cells and mouse dendritic cells
Bhutia, Y. D., Babu, E., & Ganapathy, V. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.10.021 · Cited by 55
Model of Tryptophan Metabolism, Readily Scalable Using Tissue-specific Gene Expression Data
Stavrum, A.-K., Heiland, I., Schuster, S., Puntervoll, P., & Ziegler, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.474908 · Cited by 53
Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2
Sørensen, R. B., Køllgaard, T., Andersen, R. S., van den Berg, J. H., Svane, I. M., Straten, P. T., & Andersen, M. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3403 · Cited by 53
Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion
Muller, A. J., DuHadaway, J. B., Chang, M. Y., Ramalingam, A., Sutanto‐Ward, E., Boulden, J., Soler, A. P., Mandik‐Nayak, L., Gilmour, S. K., & Prendergast, G. C. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0891-4 · Cited by 53
Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls
Kim, W. T., Yun, S. J., Yan, C., Jeong, P., Kim, Y. H., Lee, I.-S., Kang, H.-W., Park, S., Moon, S., Choi, Y. H., et al. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2016.57.4.865 · Cited by 53
Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab
Bjoern, J., Iversen, T. Z., Nitschke, N. J., Andersen, M. H., & Svane, I. M. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.05.010 · Cited by 53
Immunotherapy for Melanoma
Albittar, A. A., Alhalabi, O., & Oliva, I. C. G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_3 · Cited by 57
Indoleamine 2,3-dioxygenase is highly expressed in human adult T-cell leukemia/lymphoma and chemotherapy changes tryptophan catabolism in serum and reduced activity
Hoshi, M., Ito, H., Fujigaki, H., Takemura, M., Takahashi, T., Tomita, E., Ohyama, M., Tanaka, R., Saito, K., & Seishima, M. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.05.023 · Cited by 52
Microenvironmental Clues for Glioma Immunotherapy
Platten, M., Ochs, K., Lemke, D., Opitz, C. A., & Wick, W. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0440-1 · Cited by 53
Fused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors
Panda, S., Roy, A., Deka, S. J., Trivedi, V., & Manna, D. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00359 · Cited by 51
Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer
Mariotti, V., Han, H. S., Ismail-Khan, R. R., Tang, S., Dillon, P. M., Montero, A. J., Poklepovic, A. S., Melin, S. A., Ibrahim, N. K., Kennedy, E. P., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.5572 · Cited by 52
Indoleamine 2,3-Dioxygenase+ Cells Correspond to the BDCA2+ Plasmacytoid Dendritic Cells in Human Melanoma Sentinel Nodes
Gerlini, G., Gennaro, P. D., Mariotti, G., Urso, C., Chiarugi, A., Pimpinelli, N., & Borgognoni, L. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.307 · Cited by 51
Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin
Vareki, S. M., Rytelewski, M., Figueredo, R., Chen, D., Ferguson, P. J., Vincent, M. D., Min, W., Zheng, X., & Koropatnick, J. D. (2014) · Oncotarget · doi:10.18632/oncotarget.1916 · Cited by 53
(-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells
Ogawa, K., Hara, T., Shimizu, M., Nagano, J., Ohno, T., Hoshi, M., Ito, H., Tsurumi, H., Saito, K., Seishima, M., et al. (2012) · Oncology Letters · doi:10.3892/ol.2012.761 · Cited by 51
Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
Trojaniello, C., Luke, J. J., & Ascierto, P. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670726 · Cited by 53
Indoleamine 2,3-Dioxygenase and Regulatory Function: Tryptophan Starvation and Beyond
Orabona, C., & Grohmann, U. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-869-0_19 · Cited by 51
Natural CD4+ T-Cell Responses against Indoleamine 2,3-Dioxygenase
Ahmad, S. M., Larsen, S. K., Iversen, T. Z., Donia, M., Klausen, T. W., Svane, I. M., Straten, P. T., & Andersen, M. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034568 · Cited by 51
Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy
Buqué, A., Bloy, N., Aranda, F., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., Tartour, É., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149674 · Cited by 50
Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase
Winters, M., DuHadaway, J. B., Pham, K., Lewis-Ballester, A., Badir, S., Wai, J., Sheikh, E., Yeh, S., Prendergast, G. C., Muller, A. J., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.010 · Cited by 51
Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT
Ou, X., Cai, S., Liu, P., Zeng, J., He, Y., Wu, X., & Du, J. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0315-9 · Cited by 51
Molecular Basis for the Substrate Stereoselectivity in Tryptophan Dioxygenase
Capece, L., Lewis-Ballester, A., Marti, M. A., Estrin, D. A., & Yeh, S. (2011) · Biochemistry · doi:10.1021/bi201439m · Cited by 49
Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 – 2012)
Dolušić, E., & Frédérick, R. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.827662 · Cited by 49
Nanoengineering a metal–organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells
Fan, Q., Zuo, J., Tian, H., Huang, C., Nice, E. C., Shi, Z., & Kong, Q. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02372-8 · Cited by 51
STAT1 and STAT3 in Tumorigenesis: Two Sides of the Same Coin?
Jr., R. H. B. (2009) · CRC Press eBooks · doi:10.1201/9781498713764-13 · Cited by 50
Immunological and Nonimmunological Effects of Indoleamine 2,3-Dioxygenase on Breast Tumor Growth and Spontaneous Metastasis Formation
Levina, V. V., Su, Y., & Gorelik, E. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/173029 · Cited by 49
Targeting TDO in cancer immunotherapy
Yu, C., Song, Y., Zhu, Z., Huang, B., Xiao, Y.-Q., & Luo, D. (2017) · Medical Oncology · doi:10.1007/s12032-017-0933-2 · Cited by 51
Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3
Huang, R.-Z., Jing, X.-T., Huang, X., Pan, Y.-M., Fang, Y., Liang, G.-B., Liao, Z., Wang, H., Chen, Z., & Zhang, Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01386 · Cited by 48
Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders
Guo, Z.-H., Khattak, S., Rauf, M. A., Ansari, M. A., Alomary, M. N., Razak, S., Yang, C., Wu, D., & Ji, X. (2023) · Molecules · doi:10.3390/molecules28031283 · Cited by 49
Indoleamine-2,3-Dioxygenase in Non–Small Cell Lung Cancer
Volaric, A. K., Gentzler, R. D., Hall, R. D., Mehaffey, J. H., Stelow, E. B., Bullock, T. N. J., Martin, L. W., & Mills, A. M. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001099 · Cited by 48
Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS -Driven Sporadic Pancreatic Cancers
Nevler, A., Muller, A. J., Sutanto‐Ward, E., DuHadaway, J. B., Nagatomo, K., Londin, E. R., O’Hayer, K., Cozzitorto, J. A., Lavu, H., Yeo, T. P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0814 · Cited by 48
The Kynurenine Pathway as a Potential Target for Neuropathic Pain Therapy Design: From Basic Research to Clinical Perspectives
Ciapała, K., Mika, J., & Rojewska, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011055 · Cited by 51
IDO-Mediated Tryptophan Degradation in the Pathogenesis of Malignant Tumor Disease
Sucher, R., Kurz, K., Weiß, G., Margreiter, R., Fuchs, D., & Brandacher, G. (2010) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s4157 · Cited by 47
Synthesis and Intracellular Redox Cycling of Natural Quinones and Their Analogues and Identification of Indoleamine‐2,3‐dioxygenase (IDO) as Potential Target for Anticancer Activity
Blunt, C. E., Torcuk, C., Liu, Y., Lewis, W., Siegel, D. M., Ross, D., & Moody, C. J. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201503323 · Cited by 49
Substrate stereo‐specificity in tryptophan dioxygenase and indoleamine 2,3‐dioxygenase
Capece, L., Arrar, M., Roitberg, A. E., Yeh, S., Marti, M. A., & Estrin, D. A. (2010) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22819 · Cited by 47
The ups, downs and new trends of IDO1 inhibitors
Chen, S., Tan, J., & Zhang, A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104815 · Cited by 47
Fabrication of cisplatin-loaded polydopamine nanoparticles via supramolecular self-assembly for photoacoustic imaging guided chemo-photothermal cancer therapy
Du, X., Li, Y., Long, J., Zhang, W., Wang, D., Li, C., Zhao, M., & Lai, Y. (2021) · Applied Materials Today · doi:10.1016/j.apmt.2021.101019 · Cited by 47
Immunosuppression Routed Via the Kynurenine Pathway: A Biochemical and Pathophysiologic Approach
González, Á., Varo, N., Alegre, E., Díaz, A. A., & Melero, I. (2008) · Advances in clinical chemistry · doi:10.1016/s0065-2423(07)00007-8 · Cited by 49
The New Era of Cancer Immunotherapy
Khalil, D. N., Budhu, S., Gasmi, B., Zappasodi, R., Hirschhorn-Cymerman, D., Plitt, T., Henau, O. D., Zamarin, D., Holmgaard, R., Murphy, J. T., et al. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.010 · Cited by 46
High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia
Mabuchi, R., Hara, T., Matsumoto, T., Shibata, Y., Nakamura, N., Nakamura, H., Kitagawa, J., Kanemura, N., Goto, N., Shimizu, M., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1041388 · Cited by 47
Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story
Piro, G., Carbone, C., Carbognin, L., Pilotto, S., Ciccarese, C., Iacovelli, R., Milella, M., Bria, E., & Tortora, G. (2019) · Cancers · doi:10.3390/cancers11101525 · Cited by 47
First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington’s disease: A proposal to chemists!
Amin, S. A., Adhikari, N., Jha, T., & Gayen, S. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.10.058 · Cited by 45
Salmonellaovercomes tumor immune tolerance by inhibition of tumor indoleamine 2, 3-dioxygenase 1 expression
Kuan, Y.-D., & Lee, C. (2015) · Oncotarget · doi:10.18632/oncotarget.6258 · Cited by 46
The tumour microenvironment and implications for cancer immunotherapy
Petrulio, C., Kim‐Schulze, S., & Kaufman, H. L. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.7.671 · Cited by 45
Leukocyte Infiltration in Cancer Creates an Unfavorable Environment for Antitumor Immune Responses: A Novel Target for Therapeutic Intervention
Bronte, V., Cingarlini, S., Marigo, I., Santo, C. D., Gallina, G., Dolcetti, L., Ugel, S., Peranzoni, E., Mandruzzato, S., & Zanovello, P. (2006) · Immunological Investigations · doi:10.1080/08820130600754994 · Cited by 45
Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase
Chang, M. Y., Smith, C. B., DuHadaway, J. B., Pyle, J. R., Boulden, J., Soler, A. P., Muller, A. J., Laury‐Kleintop, L. D., & Prendergast, G. C. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.12.18142 · Cited by 45
Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration
Liu, X.-Q., Lu, K., Feng, L., Ding, M., Gao, J., Ge, X., & Wang, X. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.804917 · Cited by 45
New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation
Coluccia, A., Passacantilli, S., Famiglini, V., Sabatino, M., Patsilinakos, A., Ragno, R., Mazzoccoli, C., Sisinni, L., Okuno, A., Takikawa, O., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00718 · Cited by 45
Immunotherapy in ovarian cancer
Krishnan, V., Berek, J. S., & Dorigo, O. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.11.003 · Cited by 48
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
Budczies, J., Denkert, C., Győrffy, B., Schirmacher, P., & Stenzinger, A. (2017) · BMC Medical Genomics · doi:10.1186/s12920-017-0308-8 · Cited by 45
Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma
Kozuma, Y., Takada, K., Toyokawa, G., Kohashi, K., Shimokawa, M., Hirai, F., Tagawa, T., Okamoto, T., Oda, Y., & Maehara, Y. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.020 · Cited by 46
Folated pH-degradable nanogels for the simultaneous delivery of docetaxel and an IDO1-inhibitor in enhancing cancer chemo-immunotherapy
Qiao, H., Chen, X., Chen, E., Zhang, J., Huang, D., Yang, D., Ding, Y., Qian, H., Feijén, J., & Chen, W. (2019) · Biomaterials Science · doi:10.1039/c9bm00324j · Cited by 45
Bin1 Ablation in Mammary Gland Delays Tissue Remodeling and Drives Cancer Progression
Chang, M. Y., Boulden, J., Sutanto‐Ward, E., DuHadaway, J. B., Soler, A. P., Muller, A. J., & Prendergast, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2742 · Cited by 47
Aminophenoxazinones as Inhibitors of Indoleamine 2,3-Dioxygenase (IDO). Synthesis of Exfoliazone and Chandrananimycin A
Pasceri, R., Siegel, D. M., Ross, D., & Moody, C. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400049z · Cited by 45
Metabolites as agents and targets for cancer immunotherapy
Trefny, M. P., Kroemer, G., Zitvogel, L., & Kobold, S. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01227-z · Cited by 57
Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics
Fukuno, K., Hara, T., Tsurumi, H., Shibata, Y., Mabuchi, R., Nakamura, N., Kitagawa, J., Shimizu, M., Ito, H., Saito, K., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.953150 · Cited by 44
A novel RIPK1 inhibitor that prevents retinal degeneration in a rat glaucoma model
Do, Y., Sul, J.-W., Jang, K.-H., Kang, N. S., Kim, Y.-H., Kim, Y.-G., & Kim, E. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.08.012 · Cited by 44
Inhibition Mechanisms of Human Indoleamine 2,3 Dioxygenase 1
Lewis-Ballester, A., Karkashon, S., Batabyal, D., Poulos, T. L., & Yeh, S. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b03691 · Cited by 44
Metabolic mechanisms of cancer-induced inhibition of immune responses
Viola, A., & Bronte, V. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.005 · Cited by 45
Therapeutics targeting tumor immune escape: Towards the development of new generation anticancer vaccines
D, S. M. M., & Nitti, D. (2007) · Medicinal Research Reviews · doi:10.1002/med.20110 · Cited by 44
Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion
Saga (2010) · International Journal of Oncology · doi:10.3892/ijo_00000830 · Cited by 56
Linking Inflammation Reactions to Cancer: Novel Targets for Therapeutic Strategies
Mantovani, A., Marchesi, F., Porta, C., Allavena, P., & Sica, A. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-73898-7_9 · Cited by 43
Modification of the tumor microenvironment to enhance immunity
Liao, Y. (2007) · Frontiers in bioscience · doi:10.2741/2336 · Cited by 44
Molecular imaging and targeted therapies
Morse, D. L., & Gillies, R. J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.011 · Cited by 43
Hodgkin Disease and the Role of the Immune System
Kennedy‐Nasser, A. A., Hanley, P. J., & Bollard, C. M. (2011) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2011.557261 · Cited by 44
Thiosemicarbazide, a fragment with promising indolamine-2,3-dioxygenase (IDO) inhibition properties
Serra, S., Moineaux, L., Vancraeynest, C., Masereel, B., Wouters, J., Pochet, L., & Frédérick, R. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.05.044 · Cited by 42
Implication of indolamine 2,3 dioxygenase in the tolerance toward fetuses, tumors, and allografts
Dürr, S., & Kindler, V. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0712347 · Cited by 45
IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment
Munn, D. H., Sharma, M. D., Johnson, T. S., & Rodrı́guez, P. C. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2010-2 · Cited by 45
Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry
Coletti, A., Greco, F. A., Dolciami, D., Camaioni, E., Sardella, R., Pallotta, M. T., Volpi, C., Orabona, C., Grohmann, U., & Macchiarulo, A. (2017) · MedChemComm · doi:10.1039/c7md00109f · Cited by 42
miR‐125b‐1 and miR‐378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer
Tanaka, H., Hazama, S., Iida, M., Tsunedomi, R., Takenouchi, H., Nakajima, M., Tokumitsu, Y., Kanekiyo, S., Shindo, Y., Tomochika, S., et al. (2017) · Cancer Science · doi:10.1111/cas.13390 · Cited by 42
A metabolic switch to memory CAR T cells: Implications for cancer treatment
Rostamian, H., Fallah-Mehrjardi, K., Khakpoor-Koosheh, M., Pawelek, J. M., Hadjati, J., Brown, C. E., & Mirzaei, H. R. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.004 · Cited by 44
Developing an Effective Breast Cancer Vaccine
Soliman, H. H. (2010) · Cancer Control · doi:10.1177/107327481001700307 · Cited by 42
IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells
Vareki, S. M., Chen, D., Cresce, C. D., Ferguson, P. J., Figueredo, R., Pampillo, M., Rytelewski, M., Vincent, M. D., Min, W., Zheng, X., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143435 · Cited by 44
Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials
Girithar, H.-N., Pires, A. S., Ahn, S. B., Guillemin, G. J., Gluch, L., & Heng, B. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02245-7 · Cited by 44
Suppression of azoxymethane‐induced colonic preneoplastic lesions in rats by 1‐methyltryptophan, an inhibitor of indoleamine 2,3‐dioxygenase
Ogawa, K., Hara, T., Shimizu, M., Ninomiya, S., Nagano, J., Sakai, H., Hoshi, M., Ito, H., Tsurumi, H., Saito, K., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02237.x · Cited by 41
Expanding the view of breast cancer metabolism: Promising molecular targets and therapeutic opportunities
Harrelson, J. P., & Lee, M. W. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.07.014 · Cited by 41
Structural insights into the binding mechanism of IDO1 with hydroxylamidine based inhibitor INCB14943
Wu, Y. K., Xu, T., Liu, J., Ding, K., & Xu, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.061 · Cited by 41
Immunotherapy for Melanoma
Oliva, I. C. G., & Alqusairi, R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_2 · Cited by 41
Immunogenic cell death-inducing chemotherapeutic nanoformulations potentiate combination chemoimmunotherapy
Liu, J., Li, Z., Zhao, D., Feng, X., Wang, C., Li, D., & Ding, J. (2021) · Materials & Design · doi:10.1016/j.matdes.2021.109465 · Cited by 43
Resveratrol Targets a Variety of Oncogenic and Oncosuppressive Signaling for Ovarian Cancer Prevention and Treatment
Xu, X.-L., Deng, S., Lian, Z., & Yu, K. (2021) · Antioxidants · doi:10.3390/antiox10111718 · Cited by 43
Therapeutic Potential of Thymoquinone in Triple-Negative Breast Cancer Prevention and Progression through the Modulation of the Tumor Microenvironment
Adinew, G. M., Taka, E., Mochona, B., Badisa, R. B., MAZZIO, E. A., Elhag, R. I., & Soliman, K. F. A. (2021) · Nutrients · doi:10.3390/nu14010079 · Cited by 42
Cyclooxygenase-2 (COX-2) Inhibition Constrains Indoleamine 2,3-Dioxygenase 1 (IDO1) Activity in Acute Myeloid Leukaemia Cells
Iachininoto, M. G., Nuzzolo, E. R., Bonanno, G., Mariotti, A., Procoli, A., Locatelli, F., CRISTOFARO, R. D., & Rutella, S. (2013) · Molecules · doi:10.3390/molecules180910132 · Cited by 41
Lentivector Immunization Stimulates Potent CD8 T Cell Responses against Melanoma Self-Antigen Tyrosinase-Related Protein 1 and Generates Antitumor Immunity in Mice
Liu, Y., Peng, Y., Mi, M., Guevara-Patino, J. A., Munn, D. H., Fu, N., & He, Y. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900008 · Cited by 41
Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy
Zhang, Y., Hu, Z., Zhang, J., Ren, C., & Wang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114524 · Cited by 42
Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors
Zhou, J., Yu, L., Fan, Y., Guo, C.-H., Lv, X., Zhou, Z., Huang, H., Miao, D., Zhang, S., Li, X., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114860 · Cited by 41
Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy
Wang, Z., Li, W., Jiang, Y., Tran, T. B., Cordova, L. E., Chung, J., Kim, M., Wondrak, G. T., Erdrich, J., & Lu, J. (2023) · Nature Communications · doi:10.1038/s41467-023-43079-4 · Cited by 44
Tumor-Associated Macrophages as Targets for Tumor Immunotherapy
Weigert, A., Sekar, D., & Brüne, B. (2008) · Immunotherapy · doi:10.2217/1750743x.1.1.83 · Cited by 41

Authors: Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C.
Affiliations: Lankenau Institute for Medical Research (US)
Thomas Jefferson University (US)
Corresponding author: Prendergast, George C
ORCID: Muller, Alexander J
DuHadaway, James B
Donover, P Scott
Prendergast, George C
Venue: Nature Medicine
Publisher: Springer Science and Business Media LLC
Published: 2005-02-13
Volume: 11
Issue: 3
Pages: 312-319
ISSN: 1078-8956 (ISSN-L)
1546-170X
DOI: 10.1038/nm1196
OpenAlex: W2090410108
Cited by: 1,064
References: 54
Citations by year: 2026: 12 · 2025: 29 · 2024: 41 · 2023: 53 · 2022: 45 · 2021: 53 · 2020: 59 · 2019: 59 · 2018: 65 · 2017: 72 · 2016: 54 · 2015: 63 · 2014: 51 · 2013: 53 · 2012: 56
FWCI: 23.63
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Department of Defense
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords: indoleamine 2,3-dioxygenase, BIN1, IDO inhibitors, tumor immune evasion, antitumor immunity, STAT1, NF-κB, MMTV-Neu mice, breast cancer, combination chemotherapy, tumor immunosuppression, gene knockout
MeSH terms: Animals, Cell Transformation, Neoplastic, DNA-Binding Proteins, Drug Synergism, Enzyme Inhibitors, Indoles, Interferon-gamma, Mammary Neoplasms, Experimental, Molecular Sequence Data, Nerve Tissue Proteins, Thiohydantoins, Tryptophan Oxygenase, Trans-Activators, NF-kappa B, Paclitaxel, Tumor Escape, Tumor Suppressor Proteins, Adaptor Proteins, Signal Transducing, Indoleamine-Pyrrole 2,3,-Dioxygenase, STAT1 Transcription Factor, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks